The historical rank and industry rank for Morepen Laboratories's FCF Margin % or its related term are showing as below:
NSE:MOREPENLAB'
s FCF Margin % Range Over the Past 10 Years
Min: -10.06 Med: -0.6 Max: 6.11
Current: -7.08
During the past 13 years, the highest FCF Margin % of Morepen Laboratories was 6.11%. The lowest was -10.06%. And the median was -0.60%.
NSE:MOREPENLAB's FCF Margin % is ranked worse than 69.52% of 958
companies
in the Drug Manufacturers industry
Industry Median: 2.445
vs NSE:MOREPENLAB: -7.08
Morepen Laboratories FCF Margin % Related Terms
Morepen Laboratories FCF Margin % Historical Data
* Premium members only.
The historical data trend for Morepen Laboratories's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Morepen Laboratories's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Morepen Laboratories FCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Morepen Laboratories's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Morepen Laboratories's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Morepen Laboratories (NSE:MOREPENLAB) has a FCF Margin % of 0.00% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Morepen Laboratories and its competitors. According to the industry distribution chart, Morepen Laboratories ranks #666 out of 958 companies in the Drug Manufacturers industry, placing it in the top 69.5%.
Is Morepen Laboratories' FCF Margin % too high?
Morepen Laboratories' current FCF Margin % is 0.00%. Based on the distribution chart, Morepen Laboratories ranks #666 out of 958 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Morepen Laboratories has a GF Score™ of 74/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Morepen Laboratories' FCF Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Morepen Laboratories ranks #666 out of 958 companies for FCF Margin %. This places Morepen Laboratories in the lower half of its industry. The industry median FCF Margin % is 2.45. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.45, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Morepen Laboratories and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Morepen Laboratories's current FCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Morepen Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Morepen Laboratories (NSE:MOREPENLAB) is currently considered Fairly Valued. The stock's GF Value™ is ₹49.82, compared to a current price of ₹53.16 — trading 6.7% above its estimated fair value. The current FCF Margin % is 0.00%. Morepen Laboratories' overall GF Score™ is 74/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Morepen Laboratories (NSE:MOREPENLAB), the current FCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Morepen Laboratories (NSE:MOREPENLAB) Overvalued in 2026?
Based on GuruFocus' analysis, Morepen Laboratories stock appears to be overvalued.
The current stock price of ₹53.16 is trading 6.7% above its estimated GF Value™ of ₹49.82.
GuruFocus considers Morepen Laboratories to be Fairly Valued.
Key valuation signals for NSE:MOREPENLAB:
FCF Margin %: 0.00%
GF Value™: ₹49.82 vs. price of ₹53.16 (6.7% above fair value)
No single metric tells the full story. See the NSE:MOREPENLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Morepen Laboratories Ltd is in the business of manufacturing, producing, developing, and marketing various Active Pharmaceutical Ingredients (APIs), branded and generic formulations, and also Home Health products. Some of the products offered by the company include various drug formulations, APIs, digital thermometers, heat belts, pulse oximeters, nutritional tablets, pain sprays, and others. The company operates in a single segment namely, Pharmaceuticals. Geographically, the company derives maximum revenue from India and the rest from the United States of America, and the Rest of the world.
74GF Score
Get the complete analysis for NSE:MOREPENLAB
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:MOREPENLAB has been successfully added to your 
